228 related articles for article (PubMed ID: 33177116)
1. Inflammatory Bowel Disease Is More Common in Patients with IgA Nephropathy and Predicts Progression of ESKD: A Swedish Population-Based Cohort Study.
Rehnberg J; Symreng A; Ludvigsson JF; Emilsson L
J Am Soc Nephrol; 2021 Feb; 32(2):411-423. PubMed ID: 33177116
[TBL] [Abstract][Full Text] [Related]
2. Cancer risk in patients with immunoglobulin A nephropathy: a Swedish population-based cohort study.
Rehnberg J; Ludvigsson JF; Carrero JJ; Emilsson L
Nephrol Dial Transplant; 2022 Mar; 37(4):749-759. PubMed ID: 34788864
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: A multi-centre registry study.
Zhang L; Liu X; Pascoe EM; Badve SV; Boudville NC; Clayton PA; De Zoysa J; Hawley CM; Kanellis J; McDonald SP; Peh CA; Polkinghorne KR; Johnson DW
Nephrology (Carlton); 2016 May; 21(5):387-96. PubMed ID: 26393772
[TBL] [Abstract][Full Text] [Related]
4. Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy.
Canney M; Barbour SJ; Zheng Y; Coppo R; Zhang H; Liu ZH; Matsuzaki K; Suzuki Y; Katafuchi R; Reich HN; Cattran D; ;
J Am Soc Nephrol; 2021 Feb; 32(2):436-447. PubMed ID: 33514642
[TBL] [Abstract][Full Text] [Related]
5. The Association of Low Hemoglobin Levels with IgA Nephropathy Progression: A Two-Center Cohort Study of 1,828 Cases.
Zhu B; Liu WH; Yu DR; Lin Y; Li Q; Tong ML; Li YY; Yang RC; Du YY; Tang XL; Jiang F; Fei D; Wei XY; Zhang FF; Yin JZ; Wang WR; Li XF; Sun Y; Zhong YZ; Zhang MJ; Cheng XX; Zhu CF; Chen HY
Am J Nephrol; 2020; 51(8):624-634. PubMed ID: 32694247
[TBL] [Abstract][Full Text] [Related]
6. Clinical decision support system for end-stage kidney disease risk estimation in IgA nephropathy patients.
Pesce F; Diciolla M; Binetti G; Naso D; Ostuni VC; Di Noia T; Vågane AM; Bjørneklett R; Suzuki H; Tomino Y; Di Sciascio E; Schena FP
Nephrol Dial Transplant; 2016 Jan; 31(1):80-6. PubMed ID: 26047632
[TBL] [Abstract][Full Text] [Related]
7. Plasma Galactose-Deficient IgA1 and C3 and CKD Progression in IgA Nephropathy.
Chen P; Yu G; Zhang X; Xie X; Wang J; Shi S; Liu L; Lv J; Zhang H
Clin J Am Soc Nephrol; 2019 Oct; 14(10):1458-1465. PubMed ID: 31511226
[TBL] [Abstract][Full Text] [Related]
8. The association of normal-range serum phosphorus with immunoglobulin A nephropathy progression: a retrospective cohort study.
An X; Ding L; Yang Y; Yang Z; Zhang Y; Bai F; Liu L; Shi W; Yang X
Int Urol Nephrol; 2024 Jan; 56(1):275-282. PubMed ID: 37336802
[TBL] [Abstract][Full Text] [Related]
9. Estimated plasma osmolarity and risk of end-stage kidney disease in patients with IgA nephropathy.
Tanaka S; Nakano T; Tokumoto M; Masutani K; Tsuchimoto A; Ooboshi H; Kitazono T
Clin Exp Nephrol; 2020 Oct; 24(10):910-918. PubMed ID: 32594371
[TBL] [Abstract][Full Text] [Related]
10. Tonsillectomy delays progression of advanced IgA nephropathy to end-stage kidney disease.
Komatsu H; Fujimoto S; Kikuchi M; Sato Y; Kitamura K
Ren Fail; 2012; 34(4):448-53. PubMed ID: 22260382
[TBL] [Abstract][Full Text] [Related]
11. Patient classification and outcome prediction in IgA nephropathy.
Diciolla M; Binetti G; Di Noia T; Pesce F; Schena FP; Vågane AM; Bjørneklett R; Suzuki H; Tomino Y; Naso D
Comput Biol Med; 2015 Nov; 66():278-86. PubMed ID: 26453758
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes of tonsillectomy for IgA nephropathy patients: A retrospective cohort study, two-centre analysis with the inverse probability therapy weighting method.
Matsumoto K; Ikeda Y; Yamaguchi S; Sanematsu M; Fukuda M; Takashima T; Kishi T; Miyazono M; Uchiumi S; Yoshizaki M; Nonaka Y; Matsumoto R; Kanaya A; Fukunari K; Ikeda Y
Nephrology (Carlton); 2018 Sep; 23(9):846-854. PubMed ID: 28703898
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive agents for treating IgA nephropathy.
Natale P; Palmer SC; Ruospo M; Saglimbene VM; Craig JC; Vecchio M; Samuels JA; Molony DA; Schena FP; Strippoli GF
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD003965. PubMed ID: 32162319
[TBL] [Abstract][Full Text] [Related]
14. Preeclampsia and risk of end stage kidney disease: A Swedish nationwide cohort study.
Khashan AS; Evans M; Kublickas M; McCarthy FP; Kenny LC; Stenvinkel P; Fitzgerald T; Kublickiene K
PLoS Med; 2019 Jul; 16(7):e1002875. PubMed ID: 31361741
[TBL] [Abstract][Full Text] [Related]
15. Progression of IgA nephropathy under current therapy regimen in a Chinese population.
Li X; Liu Y; Lv J; Shi S; Liu L; Chen Y; Zhang H
Clin J Am Soc Nephrol; 2014 Mar; 9(3):484-9. PubMed ID: 24408121
[TBL] [Abstract][Full Text] [Related]
16. IgA Nephropathy Susceptibility Loci and Disease Progression.
Shi M; Ouyang Y; Yang M; Yang M; Zhang X; Huang W; Wang W; Wang Z; Zhang W; Chen X; Pan X; Ren H; Chen N; Xie J
Clin J Am Soc Nephrol; 2018 Sep; 13(9):1330-1338. PubMed ID: 30042224
[TBL] [Abstract][Full Text] [Related]
17. Mortality in IgA Nephropathy: A Nationwide Population-Based Cohort Study.
Jarrick S; Lundberg S; Welander A; Carrero JJ; Höijer J; Bottai M; Ludvigsson JF
J Am Soc Nephrol; 2019 May; 30(5):866-876. PubMed ID: 30971457
[TBL] [Abstract][Full Text] [Related]
18. Cigarette smoking and progression of IgA nephropathy.
Yamamoto R; Nagasawa Y; Shoji T; Iwatani H; Hamano T; Kawada N; Inoue K; Uehata T; Kaneko T; Okada N; Moriyama T; Horio M; Yamauchi A; Tsubakihara Y; Imai E; Rakugi H; Isaka Y
Am J Kidney Dis; 2010 Aug; 56(2):313-24. PubMed ID: 20471735
[TBL] [Abstract][Full Text] [Related]
19. Association of Infection With Human Papillomavirus and Development of End-Stage Kidney Disease in Taiwan.
Chang R; Chen ML; Lin CL; Hung YM; Wei JC
JAMA Netw Open; 2020 Oct; 3(10):e2022107. PubMed ID: 33090225
[TBL] [Abstract][Full Text] [Related]
20. Plasma D-dimer as a potential predictor of progression in IgA nephropathy: a cohort study.
Yu G; Jiang Y; Xu Z; Cheng J; Li H; Li X; Chen J
Ren Fail; 2023; 45(2):2251587. PubMed ID: 37724549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
